Oncology Venture


SEK319m market cap

SEK6.34 last close

Oncology Venture is a biopharmaceutical company with a patent-protected mRNA-based drug response predictor platform that identifies patients highly likely to respond to treatment. The company is entering Phase II with six in-licensed drugs.

Investment summary

Oncology Venture (OV) continues to provide regular response data from its ongoing LiPlaCis Phase II trial in patients with metastatic breast cancer (mBC). To date, 33% of the top one-third sub-population delineated by the drug response predictor (DRP) achieved partial remission (PR) or better. The data also suggested that tightening the LiPlaCis DRP threshold may increase response rates.

Y/E Dec
Revenue (DKKm)
EPS (ore)
P/E (x)
P/CF (x)
2016A N/A N/A N/A N/A N/A N/A
2017A 5.1 (23.8) (31.0) (127.00) N/A N/A
2018E 3.2 (38.4) (29.2) (56.99) N/A N/A
2019E 1.9 (204.6) (205.8) (382.13) N/A N/A
Last updated on 18/02/2019
Industry outlook

Oncology Venture and the DRP system have the potential to identify the value in drug assets that have otherwise been discontinued by identifying patient populations where these drugs are active. This allows the company to in-license these assets at low cost, which the company may then out-license after clinical validation.

Last updated on 18/02/2019
Share price graph
Balance sheet
Forecast net debt (DKKm) 43.5
Forecast gearing ratio (%) 30
Price performance
Actual (7.6) (28.8) (39.9)
Relative* (11.9) (32.8) (42.0)
52-week high/low SEK15.0/SEK6.1
*% relative to local index
Key management
Peter Buhl Jensen CEO
Ulla Hald Buhl Chief Operating Officer